Table 3.
Univariable analysis of risk factors for leukocyturia (LEU)
| N | LEU (N) | OR | 95% CI | p | ||
|---|---|---|---|---|---|---|
| Age (1 year increment) | 0.9 | 0.9-1.0 | 0.59 | |||
| Gender | Male | 63 | 4 | 1 | ||
| Female | 133 | 40 | 4.7 | 1.6-13.8 | < 0.01 | |
| History of tuberculosis | No | 144 | 18 | 1 | ||
| Yes | 95 | 25 | 2.5 | 1.3-4.9 | < 0.01 | |
| Hepatitis B positive | No | 215 | 38 | 1 | ||
| Yes | 12 | 2 | 1.0 | 0.2-5.1 | 0.93 | |
| Hepatitis C positive | No | 213 | 37 | 1 | ||
| Yes | 13 | 3 | 0.7 | 0.2-2.7 | 0.60 | |
| Body Mass index (0.1 kg/m2 increment) | 0.9 | 0.8-0.9 | 0.03 | |||
| History of NSAID use | No | 116 | 15 | 1 | ||
| Yes | 110 | 29 | 2.4 | 1.2-4.8 | 0.01 | |
| Current use of Cotrimoxazole | No | 53 | 2 | 1 | ||
| Yes | 181 | 42 | 7.7 | 1.8-33.3 | < 0.01 | |
| Current use of HAART | No | 67 | 7 | 1 | ||
| Yes | 171 | 37 | 2.3 | 0.9-5.6 | 0.05 | |
| Viral load (log10 copies/ml) | < 1.6 | 122 | 29 | 1 | ||
| [1.6-3.3] | 59 | 8 | 0.5 | 0.2-1.2 | ||
| [3.3-8] | 49 | 7 | 0.5 | 0.2-1.3 | 0.15 | |
| History of aminoglycosides use | No | 191 | 12 | 1 | ||
| Yes | 19 | 7 | 2.7 | 0.9-7.3 | 0.05 | |
| History of acyclovir use | No | 162 | 27 | |||
| Yes | 59 | 17 | 2.0 | 1.0-4.1 | 0.04 | |
| WHO stage | 1 | 36 | 2 | 1 | ||
| 2 | 48 | 8 | 3.7 | 0.7-18.5 | ||
| 3 | 122 | 25 | 4.4 | 0.9-19.5 | ||
| 4 | 28 | 9 | 8.0 | 1.6-41.1 | 0.03 | |
| CD4 (1 cell/mm3 increment) | 0.9 | 0.9-1.0 | 0.06 |
LEU, Leukocyturia; OR, Odds Ratio; 95% CI, 95% Confidence Interval; HAART, Highly Active Antiretroviral Therapy; NSAID, Non Steroidal Anti-Inflammatory Drugs; WHO, World Health Organization;